VMS needs a temperature check
70% of women
VMS go untreated1
Vasomotor Symptoms (VMS), also known as hot flashes and night sweats, are the most bothersome symptoms of menopause. While the number of women aged 40-65 is projected to grow, many will experience VMS and remain untreated.1-3
In the past two decades, there has been an 84% decline in FDA-approved hormone therapy prescriptions for menopause-related symptoms4
Hormone therapy (HT) remains the standard of care for VMS,
but it may not be appropriate for every patient.5-7
Treatment strategies for
- Adverse events include breast tenderness, vaginal bleeding, and bloating
- Includes a boxed warning that refers to stroke, deep vein thrombosis, endometrial cancer†, and dementia‡; estrogen therapy should not be used for the prevention of cardiovascular disease or dementia
Up to 75% reduction in frequency and 87% reduction in severity
Estrogen combined with estrogen agonist/antagonist
- Adverse events include infection, pain, arthralgia, and headache
- Includes a boxed warning that refers to stroke, deep vein thrombosis, endometrial cancer†, dementia‡, and use with additional estrogens; estrogen therapy should not be used for the prevention of cardiovascular disease or dementia
74% reduction in frequency and significant reductions in severity
Other forms of estrogen and progestin may have different risks, such as lower risk of various thromboembolism with transdermal estrogen vs oral estrogen (as indicated by some observational studies). Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
In women with a uterus who use unopposed estrogens.
In postmenopausal women 65 years of age and older.
- Adverse events include nausea, headache, and dizziness
- Includes boxed warning for suicidal thoughts and behaviors in pediatrics and young adults
33–65% reduction in frequency and significant reductions in severity
§SSRI=selective serotonin reuptake inhibitor.
No evidence of safety concerns
Inconsistent evidence of clinical benefit more than placebo
It’s time to take
VMS off the
Healthcare is trending toward targeted treatment, but VMS is lacking innovation. Other menopausal conditions like vulvovaginal atrophy (VVA) and osteoporosis have seen targeted innovations; however, VMS has seen very few.5,6,12
Women need more information about VMS
Some women struggle to differentiate burdensome symptoms
like VMS from the life stage of menopause.13
It’s time to educate
women about VMS
Research shows that women want6: